AI assistant
Sending…
ELI LILLY & Co — Director's Dealing 2022
Feb 3, 2022
29745_dirs_2022-02-03_3cec8835-8c36-4326-b8a9-56511125b737.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2022-02-01
Reporting Person: White Anne E. (SVP & Pres-Lilly Neuroscience)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-01 | Common Stock | M | 9368 | — | Acquired | 43208 | Direct |
| 2022-02-01 | Common Stock | F | 4204 | $245.39 | Disposed | 39004 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-01 | Restricted Stock Unit | $ | M | 9368 | Disposed | 2022-02-01 | Common Stock (9368.0) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
More from ELI LILLY & Co
Regulatory Filings
2026
May 20
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 8
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 6
Major Shareholding Notification
2026
May 1
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Apr 29